GSK
NEWS
In addition, Sumitomo Dainippon is acquiring an equity stake of more than 10% of Roivant shares.
Orchard Therapeutics announced data from an ongoing proof-of-concept clinical trial evaluating the safety and efficacy of OTL-203, a gene therapy for the treatment of mucopolysaccharidosis type I developed at the San Raffaele-Telethon Institute for Gene Therapy in Milan.
Orchard Therapeutics announced results from an integrated data analysis of OTL-200, a gene therapy in development for the treatment of metachromatic leukodystrophy (MLD) at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) in Milan, Italy.
World-renowned drug discovery experts to advance C4XD capabilities
The TULIP 2 trial was the second Phase III trial that assessed the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe SLE.
On Tuesday, the U.K. pharma giant optioned to license an antisense treatment from Ionis Pharmaceuticals following positive Phase II results in chronic hepatitis B virus infection.
ViiV Healthcare’s two-month injection proved to be as effective as monthly injections for HIV treatment that are currently on the market, the GlaxoSmithKline subsidiary said this morning as it continues to position itself for a leading share of the market alongside Gilead Sciences.
The American West could see some significant growth in the number of biotech jobs as companies are eying at least two states for expansions.
The company is seeking the funds to continue to drive the development of its lead candidates, nirogacestat, a gamma-secretase inhibitor for the treatment of desmoid tumors and PD-0325901, a MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
JOBS
IN THE PRESS